Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence

Pharmacology and Therapeutics

Volumn 98, Issue 2, 2003, Pages 171-195

  Allison, C ^a   Pratt, J A ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

AMPA; Benzodiazepine tolerance; Brain mapping; NMDA; Synaptic plasticity; Withdrawal

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 AMINO 3 (3 CARBOXY 5 METHYL 4 ISOXAZOLYL)PROPIONIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 5 FLUOROWILLARDIINE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID RECEPTOR; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORDIAZEPOXIDE; DIAZEPAM; FLUMAZENIL; FLUNITRAZEPAM; GLUTAMIC ACID; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; MIDAZOLAM; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PICROTOXIN; RECEPTOR; RECEPTOR SUBUNIT; RO 48 8587; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; GABAERGIC TRANSMISSION; HUMAN; KINDLING; LONG TERM POTENTIATION; LOW DRUG DOSE; MUSCLE RELAXATION; NERVE CELL PLASTICITY; NERVE TRACT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR OCCUPANCY; REGULATORY MECHANISM; REVIEW; SEDATION; SEIZURE; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

EID: 0037407779     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(03)00029-9     Document Type: Review

References (233)

1. Allison C., Dunworth S., Stephens D.N., Pratt J.A. Alterations in AMPA receptor binding during withdrawal sensitisation from benzodiazepines. Behav Pharmacol. 10(suppl. 1):1999;S2.
2. Allison C., Claase L.-A., Pratt J.A. Diazepam withdrawal-induced anxiety and place aversion in the rat: differential effects of two chronic diazepam treatment regimes. Behav Pharmacol. 13:2002;417-425.
3. Andersen P.H., Tygesen C.K., Rasmussen J.S., Soegaard-Nielsen L., Hansen A., Hansen K., Kiemer A., Stidsen C.E. Stable expression of homomeric AMPA-selective glutamate receptors in BHK cells. Eur J Pharmacol. 311:1996;95-100.
4. Arai A., Guidotti A., Costa E., Lynch G. Effect of the AMPA receptor modulator IDRA-21 on LTP in hippocampal slices. NeuroReport. 7:1996;2211-2215.
5. Arnot M.I., Davies M., Martin I.L., Bateson A.N. GABAA receptor gene expression in rat cortex: differential effects of two chronic diazepam treatment regimes. J Neurosci Res. 64:2001;617-625.
6. Ballenger J.C., Post R.M. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry. 133:1978;1-14.
7. Banke T.G., Bowie D., Lee H., Huganir R.L., Schousboe A., Traynelis S.F. Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci. 20:2000;89-102.
8. A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 50:1998;291-314.
9. Barria A., Muller D., Derkach V., Griffith L.C., Soderling T.R. Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science. 276:1997;2042-2045.
10. Bashir Z.I., Bortolotto Z.A., Davies C.H. Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature. 363:1993;347-350.
11. Becker H.C. Positive relationship between the number of prior ethanol withdrawal episodes and the severity of subsequent withdrawal seizures. Psychopharmacology. 116:1994;26-32.
12. Becker H.C., Hale R.L. Repeated episodes of ethanol withdrawal potentiate the severity of subsequent withdrawal seizures: an animal model of alcohol withdrawal "kindling" Alcohol Clin Exp Res. 17:1993;94-98.
13. Becker H.C., Diaz-Granados J.L., Hale R.L. Exacerbation of ethanol withdrawal seizures in mice with a history of multiple withdrawal experience. Pharmacol Biochem Behav. 57:1997;179-183.
14. Bekkers J.M., Stevens C.F. NMDA and non-NMDA receptors are co-localised at individual excitatory synapses in cultured rat hippocampus. Nature. 341:1989;230-233.
15. Bernard V., Bolam J.P. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur J Neurosci. 10:1998;3721-3736.
16. Bernard C., Marsden D.P., Wheal H.V. Changes in neuronal excitability and synaptic function in a chronic model of temporal lobe epilepsy. Neuroscience. 103:2001;17-26.
17. Bettler B., Mulle C. Review: neurotransmitter receptors: II. AMPA and kainate receptors. Neuropharmacology. 34:1995;123-139.
18. Bigge C.F. Ionotropic glutamate receptors. Curr Opin Chem Biol. 3:1999;441-447.
19. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
20. Bliss T.V.P., Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 232:1973;331-356.
21. Boisse N.R., Periana R.M., Guarino J.J., Kruger H.S. Acute chlordiazepoxide dependence in the rat: comparisons to chronic. NIDA Res Monogr. 67:1986;197-201.
22. Boisse N.R., Periana R.M., Guarino J.J., Kruger H.S., Samoriski G.M. Pharmacologic characterization of acute chlordiazepoxide dependence in the rat. J Pharmacol Exp Ther. 239:1986;775-783.
23. Boisse N.R., Quaglietta N., Samoriski G.M., Guarino J.J. Tolerance and physical dependence to a short-acting benzodiazepine, midazolam. J Pharmacol Exp Ther. 252:1990;1125-1133.
24. B receptor subtypes. Trends Pharmacol Sci. 11:1988;112-116.
25. Bortolotto Z.A., Clarke V.R., Delany C.M., Parry M.C., Smolders I., Vignes M., Ho K.H., Miu P., Brinton B.T., Fantaske R., Ogden A., Gates M., Ornstein P.L., Lodge D., Bleakman D., Collingridge G.L. Kainate receptors are involved in synaptic plasticity. Nature. 402:1999;297-301.
26. Boulter J., Hollmann M., O'Shea-Greenfield A., Hartley M., Deneris E., Maron C., Heinemann S. Molecular cloning and functional expression of glutamate receptor subunit genes. Science. 249:1990;1033-1037.
27. Braestrup C., Nielsen M. Iversen S.I.L., Snyder S. Handbook of Psychopharmacology. 1983;285-384 Plenum, New York.
28. Braithwaite S.P., Meyer G., Henley J.M. Interactions between AMPA receptors and intracellular proteins. Neuropharmacology. 39:2000;919-930.
29. Brett R.R., Pratt J.A. Changes in BZ-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment. Br J Pharmacol. 116:1995;2375-2384.
30. Bronson M.E. Chlordiazepoxide, but not bretazenil, produces acute dependence, as evidenced by disruptions in schedule-controlled behaviour. Pharmacol Biochem Behav. 48:1994;397-401.
31. Carlezon W.A. Jr., Rasmussen K., Nestler E.J. AMPA antagonist LY293558 blocks the development, without blocking the expression, of behavioural sensitisation to morphine. Synapse. 31:1999;256-262.
32. Chiamulera C., Albertini P., Valerio E. Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur J Pharmacol. 216:1992;335-336.
33. Chittajallu R., Braithwaite S.P., Clarke V.R., Henley J.M. Kainate receptors: subunits, synaptic localization and function. Trends Pharmacol Sci. 20:1999;26-35.
34. Choi D.W. Excitotoxic cell death. J Neurobiol. 23:1992;1261-1276.
35. Churchill L., Swanson C.J., Urbina M., Kalivas P.W. Repeated cocaine alters glutamate receptor subunit levels in the nucleus accumbens and ventral tegmental area of rats that develop behavioural sensitisation. J Neurochem. 72:1999;2397-2403.
36. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 37:1997;205-237.
37. Corda M.G., Giorgi O., Biggio G. Behavioural and biochemical evidence for a long-lasting decrease in GABAergic function elicited by chronic administration of FG 7142. Brain Res. 384:1986;60-67.
38. Corda M.G., Giorgi O., Mele S., Biggio G. Enhanced sensitivity to beta-carboline inverse agonists in rats chronically treated with FG 7142. Brain Res Bull. 19:1987;379-385.
39. Costa E., Guidotti A., Toffano G. Molecular mechanisms mediating the action of diazepam on GABA receptors. Br J Pharmacol. 133:1978;239-248.
40. Cotman C.W., Iversen L.L. Excitatory amino acids in the brain (Special Issue). Trends Neurosci. 10:1987;273-280.
41. Cotton J.L., Partin K.M. The contributions of GluR2 to allosteric modulation of AMPA receptors. Neuropharmacology. 39:2000;21-31.
42. Darstein M.B., Landwehrmeyer G.B., Feuerstein T.J. Changes in NMDA receptor subunit gene expression in the rat brain following withdrawal from forced long-term ethanol intake. Naunyn-Schmiedeberg's Arch Pharmacol. 361:2000;206-213.
43. 3H]nitro-7-sulphamoylbenzo(F)quinoxaline-2,3-dione to rat brain. J Neurochem. 67:1996;2609-2612.
44. DiChiara G., Acquas E., Tanda G., Cadoni C. Drugs of abuse: biochemical surrogates of specific aspects of natural reward. Biochem Soc Symp. 59:1993;65-81.
45. Doble A., Martin I.L. Multiple benzodiazepine receptors: no reason for anxiety. Trends Pharmacol Sci. 13:1992;76-81.
46. Dong H.L., O'Brien R.J., Fung E.T., Lanahan A.A., Worley P.F., Huganir R.L. GRIP: a synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature. 386:1997;279-284.
47. Dorow R., Horowski R., Paschelke G., Amin M., Braestrup C. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet. ii:1983;98-99.
48. Dunworth S.J., Stephens D.N. Sensitisation to repeated withdrawal, in mice treated chronically with diazepam, is blocked by an NMDA receptor antagonist. Psychopharmacology. 136:1998;308-310.
49. Durmuller N., Craggs M., Meldrum B.S. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 17:1994;167-174.
50. Ekonomou A., Smith A.L., Angelatou F. Changes in AMPA receptor binding and subunit messenger RNA expression in hippocampus and cortex in the pentylenetetrazole-induced 'kindling' model of epilepsy. Brain Res Mol Brain Res. 95:2001;27-35.
51. Falk J.L., Tang M. Development of physical dependence on midazolam by oral self-administration. Pharmacol Biochem Behav. 26:1987;797-800.
52. Farrant M., Webster R. Boulton A., Baker G., Juorio A. Drugs as Tools in Neurotransmitter Research. 1989;161-219 Humana Press, Clifton, NJ.
53. Fernandes C., File S.E. Dizocilpine does not prevent the development of tolerance to the anxiolytic effects of diazepam in rats. Brain Res. 815:1999;431-434.
54. File S.E. Tolerance to the behavioural actions of benzodiazepines. Neurosci Biobehav Rev. 9:1985;113-121.
55. File S.E. The history of benzodiazepine dependence: a review of animal studies. Neurosci Biobehav Rev. 14:1990;135-146.
56. File S.E., Fernandes C. Dizocilpine prevents the development of tolerance to the sedative effects of diazepam in rats. Pharmacol Biochem Behav. 47:1994;823-826.
57. Fitzgerald L.W., Ortiz J., Hamedani A.G., Nestler E.J. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitising agents. J Neurosci. 16:1996;274-282.
58. A receptor gene expression in adult rat hippocampus: an in situ hybridisation study. J Neurosci. 14:1994;2697-2707.
59. Gallager D.W., Lakoski J.M., Gonsalves S.F., Rauch S.L. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature. 308:1984;74-77.
60. Gallager D.W., Malcolm A.B., Anderson S.A., Gonsalves S.F. Continuous release of diazepam: electrophysiological, biochemical and behavioural consequences. Brain Res. 342:1985;26-36.
61. Gilbert M.E. The NMDA-receptor antagonist, MK-801, suppresses limbic kindling and kindled seizures. Brain Res. 463:1988;90-99.
62. Gonsalves S.F., Gallager D.W. Spontaneous and RO 15-1788-induced reversal of subsensitivity to GABA following chronic benzodiazepines. Eur J Pharmacol. 110:1985;163-170.
63. Gonsalves S.F., Gallager D.W. Time course for development of anticonvulsant tolerance and GABAergic subsensitivity after chronic diazepam. Brain Res. 405:1987;94-99.
64. 2+ influx in hippocampal CA1 neurons of gerbil. J Neurosci. 17:1997;6179-6188.
65. Grant K.A. Emerging neurochemical concepts in the actions of ethanol at ligand-gated ion channels. Behav Pharmacol. 5:1994;383-404.
66. Hawkins M., Pravica M., Radulovacki M. Chronic administration of diazepam downregulated adenosine receptors in the rat brain. Pharmacol Biochem Behav. 30:1988;303-308.
67. 3H]-5-fluorowillardiine binding in rat brain. Br J Pharmacol. 116:1995;2033-2039.
68. Hawkinson J.E., Espitia S.A. Effects of thiocyanate and AMPA receptor ligands on (S)-5-fluorowillardiine, (S)-AMPA and (R,S)-AMPA binding. Eur J Pharmacol. 329:1997;213-221.
69. Hayashi T., Umemori H., Mishina M., Yamamoto T. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature. 397:1999;72-76.
70. Heninger C., Gallager D.W. Altered gamma-aminobutyric acid/benzodiazepine interaction after chronic diazepam exposure. Neuropharmacology. 27:1988;1073-1076.
71. A subunit mRNA in rat brain. J Mol Neurosci. 2:1990;101-107.
72. Hennegriff M., Arai A., Kessler M., Vanderklish P., Mutneja M.S., Rogers G., Neve R.L., Lynch G. Stable expression of recombinant AMPA receptor subunits: binding affinities and effects of allosteric modulators. J Neurochem. 68:1997;2424-2434.
73. Hoffman P.L. Glutamate receptors in alcohol withdrawal-induced neurotoxicity. Metab Brain Dis. 10:1995;73-79.
74. Hoffman P.L., Grant K.A., Snell L.D., Reinlib L., Iorio K., Tabakoff B. NMDA receptors: role in ethanol withdrawal seizures. Ann NY Acad Sci. 654:1992;52-56.
75. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 17:1994;31-108.
76. Holmes K.H., Bilkey D.K., Laverty R., Goddard G.V. The N-methyl-D-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures. Brain Res. 506:1990;227-235.
77. A receptor subunit mRNAs in the rat cortex. Neuropharmacology. 35:1996;1457-1463.
78. Holt R.A., Bateson A.N., Martin I.L. Decreased GABA enhancement of benzodiazepine binding after a single dose of diazepam. J Neurochem. 72:1999;2219-2222.
79. 3H]AMPA, a structural analogue of glutamic acid, to rat brain membranes. J Neurochem. 38:1982;173-178.
80. 3H]CNQX binds with equal affinity to two agonist states of quisqualate receptors. Biochem Pharmacol. 38:1989;3207-3212.
81. Hunkeler W., Moehler H., Pieri L. Selective antagonists of benzodiazepines. Nature. 290:1981;514-516.
82. Hunt W.A. Are binge drinkers more at risk of developing brain damage? Alcohol. 10:1993;559-561.
83. Impagnatiello F., Pesold C., Longone P., Caruncho H., Fritschy J.M., Costa E., Guidotti A. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. Mol Pharmacol. 49:1996;822-831.
84. Izzo E., Auta J., Impagnatiello F., Pesold C., Guidotti A., Costa E. Glutamic acid decarboxylase and glutamate receptor changes during tolerance and dependence to benzodiazepines. Proc Natl Acad Sci USA. 98:2001;3483-3488.
85. Jackson A., Mead A.N., Rocha B.A., Stephens D.N. AMPA receptors and motivation for drug: effect of the selective antagonist NBQX on behavioural sensitisation and on self-administration in mice. Behav Pharmacol. 9:1998;457-467.
86. Jeevanjee F., Johnson A.M., Loudon J.M., Nicholass J.M. Is FG7142 mediated kindling due to changes in efficacy at the BZ/GABA receptor complex? Br J Pharmacol. 84:1985;188P.
87. Kamphuis W., Monyer H., De Rijk T.C., Lopes da Silva F.H. Hippocampal kindling increases the expression of glutamate receptor-A Flip and -B Flip mRNA in dentate granule cells. Neurosci Lett. 148:1992;51-54.
88. Kamphuis W., De Rijk T.C., Talamini L.M., Lopes da Silva F.H. Rat hippocampal kindling induces changes in the glutamate receptor mRNA expression patterns in dentate granule neurons. Eur J Neurosci. 6:1994;1119-1127.
89. Kang I., Miller L.G. Decreased GABAA receptor subunit mRNA concentrations following chronic lorazepam administration. Br J Pharmacol. 103:1991;1285-1287.
90. Karler R., Calder L.D., Chaudhry I.A., Turkanis S.A. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci. 45:1989;599-606.
91. Keinanen K., Wisden W., Sommer B., Werner P., Herb A., Verdoorn T.A., Sakmann B., Seeburg P.H. A family of AMPA-selective glutamate receptors. Science. 249:1990;556-560.
92. Kodama M., Yamada N., Sato K., Kitamura Y., Koyama F., Sato T., Morimoto K., Kuroda S. Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat. Eur J Pharmacol. 374:1999;11-19.
93. Koff J.M., Pritchard G.A., Greenblatt D.J., Miller L.G. The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. Pharmacology. 55:1997;217-227.
94. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
95. Lader M.H., File S.E. The biological basis of benzodiazepine dependence. Psychol Med. 17:1987;539-547.
96. Lason W., Turchan J., Przewlocka B., Labuz D., Machelska H., Przewlocki R. Effects of pentylenetetrazol kindling on glutamate receptor genes expression in the rat hippocampus. Brain Res. 785:1998;355-358.
97. Lauri S.E., Delany C., Clarke V.R.J., Bortolotto Z.A., Ornstein P.L., Isaac J.T.R., Collingridge G.L. Synaptic activation of a presynaptic kainate receptor facilitates AMPA receptor-mediated synaptic transmission at hippocampal mossy fibre synapses. Neuropharmacology. 41:2001;907-915.
98. Laurie D.J., Pratt J.A. Local cerebral glucose utilisation following subacute and chronic diazepam treatment: differential tolerance. Brain Res. 504:1989;101-111.
99. Laurie D.J., Pratt J.A. Flumazenil induces localised increases in glucose utilisation during diazepam withdrawal in rats. Brain Res. 631:1993;277-286.
100. Lee S., Miskovsky J., Williamson J., Howells R., Devinsky O., Lothman E., Christakos S. Changes in glutamate receptor and proenkephalin gene expression after kindled seizures. Brain Res Mol Brain Res. 24:1994;34-42.
101. Leonard A.S., Davare M.A., Horne M.C., Garner C.C., Hell J.W. SAP97 is associated with the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit. J Biol Chem. 273:1998;19518-19524.
102. Li Y., Vartanian A.J., White F.J., Xue C.J., Wolf M.E. Effects of the AMPA receptor antagonist NBQX on the development and expression of behavioural sensitisation to cocaine and amphetamine. Psychopharmacology. 134:1997;266-276.
103. Liao D., Hessler N.A., Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature. 375:1995;400-404.
104. Lipton S.A., Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 330:1994;613-622.
105. Lissin D.V., Gomperts S.N., Carroll R.C., Christine C.W., Kalman D., Kitamura M., Hardy S., Nicoll R.A., Malenka R.C., von Zastrow M. Activity differentially regulates the surface expression of synaptic AMPA and NMDA receptors. Proc Natl Acad Sci USA. 95:1998;7097-7102.
106. Little H.J., Nutt D.J., Taylor S.C. Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling. Br J Pharmacol. 83:1984;951-958.
107. Little H.J., Nutt D.J., Taylor S.C. The effects of drugs acting at the GABAA-receptor/ionophore after chemical kindling with the benzodiazepine receptor ligand FG 7142. Br J Pharmacol. 88:1986;507-514.
108. Little H.J., Gale R., Sellars N., Nutt D.J., Taylor S.C. Chronic benzodiazepine treatment increases the effects of the inverse agonist FG7142. Neuropharmacology. 27:1988;383-389.
109. Lo D.C. Neurotrophic factors and synaptic plasticity. Neuron. 15:1995;979-981.
110. Lomeli H., Mosbacher J., Melcher T., Hoger T., Geiger J.R., Kuner T., Monyer H., Higuchi M., Bach A., Seeburg P.H. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science. 266:1994;1709-1713.
111. Loscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol. 54:1998;721-741.
112. Loscher W., Stephens D.N. Chronic treatment with diazepam or the inverse benzodiazepine receptor agonist FG 7142 causes differential changes in the effects of GABA receptor stimulation. Epilepsy Res. 2:1988;253-259.
113. Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., Fritschy J.M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 290:2000;131-134.
114. Lu W.X., Wolf M.E. Repeated amphetamine administration alters AMPA receptor subunit expression in rat nucleus accumbens and medial prefrontal cortex. Synapse. 32:1999;119-131.
115. A receptor subunits. Trends Pharmacol Sci. 12:1991;49-51.
116. A receptor channels. Annu Rev Neurosci. 17:1994;569-602.
117. Maier D.M., Pohorecky L.A. The effect of repeated withdrawal episodes on subsequent withdrawal severity in ethanol-treated rats. Drug Alcohol Depend. 23:1989;103-110.
118. Malenka R.C. Synaptic plasticity in the hippocampus: LTP and LTD. Cell. 78:1994;535-538.
119. Malva J.O., Carvalho A.P., Carvalho C.M. Kainate receptors in hippocampal CA3 subregion: evidence for a role in regulating neurotransmitter release. Neurochem Int. 32:1998;1-6.
120. Maren S., Tocco G., Standley S., Baudry M., Thompson R.F. Postsynaptic factors in the expression of long-term potentiation (LTP): increased glutamate receptor binding following LTP induction in vivo. Proc Natl Acad Sci USA. 90:1993;9654-9658.
121. Mariott S., Tyrer P. Benzodiazepine dependence - avoidance and withdrawal. Drug Safety. 9:1993;93-103.
122. Marksitzer R., Benke D., Fritschy J.M., Trzeciak A., Bannwarth W., Mohler H. GABAA-receptors: drug binding profile and distribution of receptors containing the alpha 2-subunit in situ. J Recept Res. 13:1993;467-477.
123. Marley R.J., Heninger C., Hernandez T.D., Gallager D.W. Chronic administration of beta-carboline-3-carboxylic acid methylamide by continuous intraventricular infusion increases GABAergic function. Neuropharmacology. 30:1991;245-251.
124. Martin L.J., Blackstone C.D., Huganir R.L., Price D.L. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron. 9:1992;259-270.
125. McDonald J.W., Fix A.S., Tizzano J.P., Schoepp D.D. Seizures and brain injury in neonatal rats induced by 1S,3R-ACPD, a metabotropic glutamate receptor agonist. J Neurosci. 13:1993;4445-4455.
126. McGlade-McCulloh E., Yamamoto H., Tan S.E., Brickey D.A., Soderling T.R. Phosphorylation and regulation of glutamate receptors by calcium/calmodulin-dependent protein kinase II. Nature. 362:1993;640-642.
127. A receptor subtypes really occur in the brain? Trends Neurosci. 19:1996;139-143.
128. McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macaulay A., Brown N., Howell O., Moore K.W., Carling R.W., Street L.J., Castro J.L., Ragan C.I., Dawson G.R., Whiting P.J. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 3:2000;587-592.
129. Mead A.N., Stephens D.N. AMPA receptors are involved in the expression of amphetamine-induced behavioural sensitisation, but not in the expression of amphetamine-induced conditioned activity in mice. Neuropharmacology. 37:1998;1131-1138.
130. Meldrum B.S., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci. 11:1990;379-387.
131. Mele L., Sagratella S. Chronic administration of diazepam to rats causes changes in EEG patterns and in coupling between GABA receptors and benzodiazepine binding sites in vitro. Brain Res. 323:1984;93-102.
132. Mierlak D., Farb D.H. Modulation of neurotransmitter receptor desensitisation: chlordiazepoxide stimulates fading of the GABA response. Neuroscience. 8:1988;814-820.
133. Miller L.G., Greenblatt D.J., Roy R.B., Summer W.R., Shader R.I. Chronic benzodiazepine administration: II. Discontinuation syndrome is associated with upregulation of gamma-aminobutyric acidA receptor complex binding and function. J Pharmacol Exp Ther. 246:1988;177-182.
134. Mohler H., Okada T. Benzodiazepine receptors demonstrated in the central nervous system. Science. 198:1977;849-851.
135. Molnar E., Baude A., Richmond S.A., Patel P.B., Somogyi P., McIlhinney R.A.J. Biochemical and immunocytochemical characterisation of antipeptide antibodies to a cloned GluR1 glutamate receptor subunit: cellular and subcellular distribution in the rat forebrain. Neuroscience. 53:1993;307-326.
136. Monaghan D.T., Yao D., Cotman C.W. Distribution of [3H]AMPA binding sites in rat brain as determined by quantitative autoradiography. Brain Res. 324:1984;160-164.
137. Monaghan D.T., Bridges R.J., Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol. 29:1989;365-402.
138. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 12:1994;529-540.
139. Moriyoshi K., Masu M., Ishii T., Shigemoto R., Mizuno N., Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 354:1991;31-37.
140. Murphy S.M., Tyrer P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry. 158:1991;511-516.
141. 3H]Ro48 8587 in rat brain. J Neurochem. 71:1998;418-426.
142. Namba T., Morimoto K., Sato K., Yamada N., Kuroda S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 638:1994;36-44.
143. 3H](-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid binding sites. J Neurochem. 54:1990;686-695.
144. Nutt D.J. Benzodiazepine dependence in the clinic: reason for anxiety. Trends Neurosci. 8:1986;457-460.
145. A receptor subunit mRNA in rat brain following flurazepam treatment. J Psychopharmacol. 6:1992;364-369.
146. O'Donovan M.C., Buckland P.R., Spurlock G., McGuffin P. Bi-directional changes in the levels of messenger RNAs encoding gamma-aminobutyric acidA receptor alpha subunits after flurazepam treatment. Eur J Pharmacol. 226:1992;335-341.
147. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 53:1993;1009-1018.
148. Okazaki M.M., McNamara J.O., Nadler J.V. Kainate and quisqualate receptor autoradiography in rat brain after angular bundle kindling. Neuroscience. 1:1990;135-152.
149. A receptors. FASEB J. 4:1990;1469-1480.
150. 3H]AMPA binding to glutamate receptor subpopulations in rat brain. Brain Res. 402:1987;243-254.
151. Pellegrini-Giampietro D.E., Bennett M.V.L., Zukin R.S. Differential expression of three glutamate receptor genes in developing rat brain: an in situ hybridisation study. Proc Natl Acad Sci USA. 88:1991;4157-4161.
152. A receptor by depressant barbiturates and pregnane steroids. Br J Pharmacol. 94:1988;1257-1269.
153. Petralia R.S., Wenthold R.J. Light and electron immunocytochemical localisation of AMPA selective glutamate receptors in the rat brain. J Comp Neurol. 318:1992;329-354.
154. Petursson H. The benzodiazepine withdrawal syndrome. Addiction. 89:1994;1455-1459.
155. Polc P. Electrophysiology of benzodiazepine receptor ligands: multiple mechanisms and sites of action. Prog Neurobiol. 31:1988;349-423.
156. Pratt J.A., Brett R.R., Laurie D.J. Benzodiazepine dependence: from neural circuits to gene expression. Pharmacol Biochem Behav. 59:1998;925-934.
157. Prince H.K., Conn P.J., Blackstone C.D., Huganir R.L., Levey A.I. Down-regulation of AMPA receptor subunit GluR2 in amygdaloid kindling. J Neurochem. 64:1995;462-465.
158. Pritchard G.A., Galpern W.R., Lumpkin M., Miller L.G. Chronic benzodiazepine administration: VIII. Receptor upregulation produced by chronic exposure to the inverse agonist FG-7142. J Pharmacol Exp Ther. 258:1991;280-285.
159. A receptor subunit for benzodiazepine pharmacology. Nature. 338:1989;582-585.
160. 3H]AMPA, a structural analogue of glutamic acid. Brain Res. 309:1984;173-177.
161. Rickels K., Schweizer E., Case W.G., Greenblatt D.J. Long-term therapeutic use of BZs: I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 47:1990;899-907.
162. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitisation theory of addiction. Brain Res Rev. 18:1993;247-291.
163. Roca D.J., Rozenberg I., Farrant M., Farb D.H. Chronic agonist exposure induces downregulation and allosteric uncoupling of the GABA/benzodiazepine receptor complex. Mol Pharmacol. 37:1990;37-43.
164. Roche K.W., O'Brien R.J., Mammen A.L., Bernhardt J., Huganir R.L. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron. 16:1996;1179-1188.
165. Rogawski M.A. Excitatory amino acids and seizures. Stone T.W. CNS Neurotransmitters and Neuromodulators: Glutamate. 1995;219-237 CRC Press, Boca Raton, FL.
166. Rogawski M.A., Kurzman P.S., Yamaguchi S.I., Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology. 40:2001;28-35.
167. Rosenberg H.C., Chiu T.H. Tolerance during chronic benzodiazepine treatment associated with decreased receptor binding. Eur J Pharmacol. 70:1981;453-460.
168. Rudolph U., Crestani F., Benke D., Brunig I., Benson J.A., Fritschy J.M., Martin J.R., Bluethmann H., Mohler H. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 401:1999;796-800.
169. Rudolph U., Crestani F., Mohler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci. 22:2001;188-194.
170. Sato K., Morimoto K., Okamoto M. Anticonvulsant action of a non-competitive antagonist of NMDA receptors (MK-801) in the kindling model of epilepsy. Brain Res. 463:1988;12-20.
171. Schneider H.H., Stephens D.N. Co-existence of kindling induced by the beta-carboline, FG 7142, and tolerance to diazepam following chronic treatment in mice. Eur J Pharmacol. 154:1988;35-45.
172. A receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature. 314:1985;168-171.
173. Schoepp D.D., Conn P.J. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci. 14:1993;13-20.
174. A receptor: molecular biology reveals a complex picture. Trends Pharmacol Sci. 10:1989;476-478.
175. Schofield P.R., Darlison M.G., Fujita N., Burt D.R., Stephenson F.A., Rodriguez H., Rhee L.M., Ramachandran J., Reale V., Glencorse T.A., Seeburg P.H., Barnard E.A. Sequence and functional expression of the GABA A receptor shows a ligand-gated receptor super-family. Nature. 328:1987;221-227.
176. Schroeder H., Becker A., Hoellt V. Sensitivity and density of glutamate receptor subtypes in the hippocampal formation are altered in pentylenetetrazole-kindled rats. Exp Brain Res. 120:1998;527-530.
177. Schroeder H., Becker A., Schroeder U., Hoellt V. 3H-L-glutamate binding and 3H-D-aspartate release from hippocampal tissue during the development of pentylenetetrazole kindling in rats. Pharmacol Biochem Behav. 62:1999;349-352.
178. Seivewright N., Dougal W. Withdrawal symptoms from high dose benzodiazepines in poly drug users. Drug Alcohol Depend. 32:1993;15-23.
179. A receptors on channel function. Neuron. 5:1990;703-711.
180. Sloan J.W., Martin W.R., Wala E. Duration of diazepam (dz) treatment and the intensity of flumazenil precipitated abstinence (fpa) in dogs. FASEB J. 5:1991;703.
181. Sloan J.W., Martin W.R., Wala E. Effect of the chronic dose of diazepam on the intensity and characteristics of the precipitated abstinence syndrome in the dog. J Pharmacol Exp Ther. 265:1993;1152-1162.
182. Snell L.D., Nunley K.R., Lickteig R.L., Browning M.D., Tabakoff B., Hoffman P.L. Regional and subunit specific changes in NMDA receptor mRNA and immunoreactivity in mouse brain following chronic ethanol ingestion. Brain Res Mol Brain Res. 40:1996;71-78.
183. Sommer B., Seeberg P.H. Glutamate receptor channels - novel properties and new clones. Trends Pharmacol Sci. 13:1992;291-296.
184. Sommer B., Keinanen K., Verdoorn T.A., Wisden W., Burnashev N., Herb A., Kohler M., Takagi T., Sakmann B., Seeburg P.H. Flip and flop: a cell-specific functional switch in glutamate operated channels of the CNS. Science. 249:1990;1580-1585.
185. Sommer B., Kohler M., Sprengel R., Seeburg P.H. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell. 67:1991;11-19.
186. Squires R.F., Braestrup C. Benzodiazepine receptors in rat brain. Nature. 266:1977;732-734.
187. Srivastava S., Osten P., Vilim F.S., Khatri L., Inman G., States B., Daly C., DeSouza S., Abagyan R., Valtschanoff J.G., Weinberg R.J., Ziff E.B. Novel anchorage of GluR2/3 to the postsynaptic density by the AMPA receptor-binding protein ABP. Neuron. 21:1998;581-591.
188. Staubli U., Perez Y., Xu F.B., Rogers G., Ingvar M., Stone-Elander S., Lynch G. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci USA. 91:1994;11158-11162.
189. Staubli U., Rogers G., Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA. 91:1994;777-781.
190. Stensbol T.B., Slok F.A., Trometer J., Hurt S., Ebert B., Kjoller C., Egebjerg J., Madsen U., Diemer N.H., Krogsgaard-Larsen P. Characterization of a new AMPA receptor radioligand, [3H]2-amino-3-(3-carboxy-5-methyl-4-isoxazolyl)propionic acid. Eur J Pharmacol. 373:1999;251-262.
191. Stephens D.N. A glutamatergic hypothesis of drug dependence. Behav Pharmacol. 6:1995;425-446.
192. Stephens D.N., Schneider H.H. Tolerance to the benzodiazepine diazepam, in an animal model of anxiety. Psychopharmacology. 87:1985;322-327.
193. Stephens D.N., Turski L. Kindling to the benzodiazepine receptor inverse agonist FG 7142: evidence for involvement of NMDA, but not non-NMDA glutamatergic receptors. Neuropharmacology. 32:1993;1011-1017.
194. Stephens D.N., Weidmann R. Blockade of FG 7142 kindling by anticonvulsants acting at sites removed from the benzodiazepine receptor. Brain Res. 492:1989;89-98.
195. Stephens D.N., Turski L., Turner J.D., Schneider H.H. Are changes in glutamatergic mechanisms responsible for kindling to the benzodiazepine receptor inverse agonist FG 7142? Br J Pharmacol. 98:1989;837P.
196. Stephens D.N., Andrews J.S., Turski L., Schneider H.H. Excitatory amino acids and anxiety. Briley M., File S.E. New Concepts in Anxiety. 1991;366-381 Macmillan, Basingstroke.
197. Steppuhn K.G., Turski L. Diazepam dependence prevented by glutamate antagonists. Proc Natl Acad Sci. 90:1993;6889-6893.
198. Suzuki T., Shimizu M., Tsuda M., Soma M., Misawa M. Role of metabotropic glutamate receptors in the hypersusceptibility to pentylenetetrazole-induced seizures during diazepam withdrawal. Eur J Pharmacol. 369:1999;163-168.
199. Tallman J.F., Gallager D.W. The GABAergic system: a locus of benzodiazepine action. Annu Rev Neurosci. 8:1985;21-44.
200. Tallman J.F., Thomas J.W., Gallager D.W. GABAergic modulation of benzodiazepine binding site sensitivity. Nature. 274:1978;383-385.
201. Tallman J.F., Paul S.M., Skolnick P., Gallager D.W. Receptors for the age of anxiety: pharmacology of the benzodiazepines. Science. 207:1980;274-281.
202. Tan S.E., Wenthold R.J., Soderling T.R. Phosphorylation of AMPA-type glutamate receptors by calcium/calmodulin-dependent protein kinase II and protein kinase C in cultured hippocampal neurons. J Neurosci. 14:1994;1123-1129.
203. Tanabe Y., Nomura A., Masu M., Shigemoto R., Mizuno N., Nakanishi S. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci. 13:1993;1372-1378.
204. Tietz E.I., Rosenberg H.C., Chiu T.H. Autoradiographic localisation of benzodiazepine receptor downregulation. J Pharmacol Exp Ther. 236:1986;284-292.
205. A receptor subunit mRNAs measured in situ in rat hippocampus and cortex following chronic flurazepam. J Mol Neurosci. 4:1993;277-292.
206. Trevisan L., Fitzgerald L.W., Brose N., Gasic G.P., Heinemann S.F., Duman R.S., Nestler E.J. Chronic ingestion of ethanol up-regulates NMDAR1 receptor subunit immunoreactivity in rat hippocampus. Neurochemistry. 62:1994;1635-1638.
207. Tsuda M., Chiba Y., Suzuki T., Misawa M. Upregulation of NMDA receptor subunit proteins in the cerebral cortex during diazepam withdrawal. Eur J Pharmacol. 341:1998;R1-R2.
208. Tsuda M., Shimizu N., Yajima Y., Suzuki T., Misawa M. Hypersusceptibility to DMCM-induced seizures during diazepam withdrawal in mice: evidence for upregulation of NMDA receptors. Naunyn-Schmiedeberg's Arch Pharmacol. 357:1998;309-315.
209. Tsuda M., Suzuki T., Misawa M. NMDA receptor antagonists potently suppress the spontaneous withdrawal signs induced by discontinuation of long-term diazepam treatment in Fischer 344 rats. Brain Res. 790:1998;82-90.
210. Tyrer P., Owen R., Dawling S. Gradual withdrawal of diazepam after long-term therapy. Lancet. i:1983;1402-1406.
211. Tzschentke T.M., Schmidt W.J. Interactions of MK801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitisation. Behav Brain Res. 84:1997;99-107.
212. Uhlenhuth E.H., Balter M.B., Ban T.A., Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J Clin Psychopharmacol. 19(suppl. 2):1999;23S-29S.
213. Ulrichsen J., Bech B., Ebert B., Diemer N.H., Allerup P., Hemmingsen R. Glutamate and benzodiazepine receptor autoradiography in rat brain after repetition of alcohol dependence. Psychopharmacology. 126:1996;31-41.
214. Vignes M. Regulation of spontaneous inhibitory synaptic transmission by endogenous glutamate via non-NMDA receptors in cultured rat hippocampal neurons. Neuropharmacology. 40:2001;737-748.
215. Wang Y., Small D.L., Stanimirovic D.B., Morley P., Durkin J.P. AMPA receptor-mediated regulation of a Gi-protein in cortical neurons. Nature. 389:1997;502-504.
216. Ward B.O., Stephens D.N. Sensitisation of withdrawal signs following repeated withdrawal from a benzodiazepine: differences between measures of anxiety and seizure sensitivity. Psychopharmacology. 135:1998;342-352.
217. Wenthold R.J., Yokotani N., Doi K., Wada K. Immunochemical characterisation of the non-NMDA glutamate receptor using subunit-specific antibodies. Evidence for a hetero-oligomeric structure in rat brain. J Biol Chem. 267:1992;501-507.
218. Wenthold R.J., Petralia R.S., Blahos J. II, Niedzielski A.S. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci. 16:1996;1982-1989.
219. Whetsell W.O.J. Current concepts of excitotoxicity. J Neuropathol Exp Neurol. 55:1996;1-13.
220. Wilson M.A., Gallager D.W. Ro 15-1788-induced seizures in rats continually exposed to diazepam for prolonged periods. Epilepsy Res. 2:1988;14-19.
221. Wisden W., Laurie D.J., Monyer H., Seeburg P.H. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain: I. Telencephalon, diencephalon, mesencephalon. J Neurosci. 12:1992;1040-1062.
222. Wolf M.E. The role of excitatory amino acids in behavioural sensitisation to psychomotor stimulants. Prog Neurobiol. 54:1998;679-720.
223. Wolf M.E., Jeziorski M. Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioural sensitisation. Brain Res. 613:1993;291-294.
224. Wolf M.E., Dahlin S.L., Hu X.T., Xue C.J., White K. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioural sensitisation to amphetamine: comparison with N-methyl-D-aspartate antagonists. Neuroscience. 69:1995;417-439.
225. Woods J.H., Katz J.L., Winger G. Abuse liability of benzodiazepines. Pharmacol Rev. 39:1987;251-338413.
226. Woods J.H., Katz J.L., Winger G. Benzodiazepines: use, abuse and consequences. Pharmacol Rev. 44:1992;151-338.
227. Woods J.H., Katz J.L., Winger G. Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1777-1790 Raven Press, New York.
228. Wyneken U., Smalla K.H., Marengo J.J., Soto D., de la Cerda A., Tischmeyer W., Grimm R., Boeckers T.M., Wolf G., Orrego F., Gundelfinger E.D. Kainate-induced seizures alter protein composition and N-methyl-D-aspartate receptor function of rat forebrain postsynaptic densities. Neuroscience. 102:2001;65-74.
229. Xia J., Zhang X., Staudinger J., Huganir R.L. Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron. 22:1999;179-187.
230. Yamakura T., Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol. 59:1999;279-298.
231. Young A.B., Fagg G.E. Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol Sci. 11:1990;126-133.
232. 5 subunit mRNAs in brain regions of flurazepam treated rats. Mol Pharmacol. 45:1994;657-663.
233. Zivkovic I., Thompson D.M., Bertolino M., Uzunov D., DiBella M., Costa E., Guidotti A. 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther. 272:1995;300-309.